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Background: ADHD is a common childhood onset mental health disorder that persists into adulthood in
two-thirds of cases. One of the most prevalent and impairing comorbidities of ADHD in adults are substance use
disorders. We estimate rates of ADHD in patients with substance abuse disorders and delineate impairment in the
co-morbid group.
Method: Screening for ADHD followed by a research diagnostic interview in people attending in-patient drug and
alcohol detoxification units.
Results: We estimated prevalence of undiagnosed ADHD within substance use disorder in-patients in South
London around 12%. Those individuals with substance use disorders and ADHD had significantly higher self-rated
impairments across several domains of daily life; and higher rates of substance abuse and alcohol consumption,
suicide attempts, and depression recorded in their case records.
Conclusions: This study demonstrates the high rates of untreated ADHD within substance use disorder populations
and the association of ADHD in such patients with greater levels of impairment. These are likely to be a source of
additional impairment to patients and represent an increased burden on clinical services.Background
ADHD is a common childhood onset mental health dis-
order defined by the presence of impairing levels of
hyperactive, impulsive and inattentive symptoms. The
disorder has an estimated prevalence during childhood
in the United Kingdom of 3.6% [1]. Longitudinal follow
up studies find that around two-thirds of cases continue
to be impaired by ADHD symptoms in adulthood, with
an estimated worldwide prevalence for the disorder in
adults of around 2.5% [2]. Despite the high rate of
ADHD in adults, the disorder remains under-diagnosed
and under-treated beyond the adolescent years [3]. This
is a particular issue for adult mental health because
ADHD symptoms lead not only to impairments in* Correspondence: philip.asherson@kcl.ac.uk
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reproduction in any medium, provided the oracademic, occupational and social functioning, but are
also associated with the development of comorbid dis-
orders including anxiety, depression, personality dis-
order, antisocial behaviour and substance use disorders
(SUD) [4-7]. This raises the question of whether people
diagnosed with such conditions may in some cases have
undiagnosed and untreated ADHD; and whether treat-
ment of underlying ADHD may lead to improvements
in their comorbid disorder. Among the most frequent
comorbidities associated with ADHD are substance use
disorders. A bi-directional link between ADHD and
SUD has been reported, with increased rates of SUD
within ADHD populations and increased rates of
ADHD within SUD populations [8-10]. Previous studies
of ADHD in the United States and Europe estimate very
high prevalence rates for lifetime SUD of up to 58%
[11]. These studies found that alcohol and cannabis are
the most frequently abused substances [8] followed byl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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methodological issues that may inflate prevalence rates,
indicated by the wide range in reported prevalence rates
for ADHD in SUD populations of around 10% to 55%
[13,14]. Challenges to the correct identification of ADHD
in SUD settings include high drop-out rates between
screening and assessment stages; and the potential overlap
of symptoms between the two disorders [15] including
intoxication and withdrawal states [12] and the long-term
effects of chronic drug use on brain function [16-18] that
could mimic ADHD. Retrospective recall of childhood
ADHD symptoms is particularly challenging in SUD
populations due to impaired memory and the often com-
plex histories with adverse psychosocial risk factors for the
development of behavioural problems. Informant reports
are often not available in SUD populations because rela-
tionships with informants are frequently strained [12] and
for this reason most studies depend on self-report. When
evaluating ADHD, few papers report the time since last
substance use, although delayed screening until three
weeks of abstinence has been reported [19]. Lastly, it has
been reported that autism is frequently unrecognized in
people with ADHD and this may generate additional
impairments in SUD populations.
This study addresses some of these concerns by imple-
menting a systematic screening protocol for ADHD in
London (UK) SUD clinics, with the aim of estimating the
rate of undiagnosed and untreated ADHD within SUD
patients; and evaluating whether those with comorbid
ADHD and SUD experience greater impairment, in terms
of co-morbid diagnoses, previous convictions or suicide
attempts than those with SUD alone. We also carried out
an investigation of autistic traits in this population to de-




Sample characteristics are listed in Table 1. Participants
(n=226) were recruited from two in-patient alcohol and
drug detoxification and stabilisation units in South-East
London. Consecutive admissions to the in-patient units
were invited to take part in the study over an 18-month
(Clinic 1) or 11-month (Clinic 2) period. Of these 74% hadTable 1 Sample characteristics
Total sample size N=226
Male gender 173 (76.5%)
Mean age* 39.0 (SD 10.3)
Ethnicity* 183 (81.0%) White European
Alcohol dependence* 112 (49.6%)
Drug dependence* 29 (12.8%)
Alcohol and drug dependence* 85 (37.6%)previously attended a detoxification treatment program.
One participant already had a current adult diagnosis of
ADHD and two had a recorded childhood diagnosis of
ADHD. We excluded individuals with a history of current
or recent psychosis (n=4), current serious physical illness
(n=3), insufficient understanding of English to give
informed consent (n=6) and lack of capacity to consent
(n=2). Overall 51% of patients approached agreed to
participate. Study participants received no payment for
participation.
Study procedures
The study of people undergoing inpatient detoxification
included two screening stages using ADHD rating scale
data, followed by formal evaluation of the diagnosis of
ADHD using a semi-structured interview for DSM-IV
ADHD. By including two screening steps (T1 and T2) we
were able to evaluate the difference between the level of
ADHD symptoms on admission (T1) and one week later
(T2), when they had been detoxified or stabilised on treat-
ments such as methadone. Screening assessment session
one (T1) took place soon after admission (mean day 5, SD
4). The second screening assessment session (T2) was com-
pleted as close as possible to seven days after the T1 assess-
ment (mean 8 days, SD 6). During the T1 session, patients
completed current and childhood symptom checklists for
DSM-IV ADHD; and during the T2 session current symp-
toms only, since it was assumed that only the report of
current levels of symptoms would be affected by state of
detoxification and current drug use and needed to be mea-
sured at both time points. In addition whenever possible
we obtained contact details from informants for childhood
and current ADHD symptoms who were asked to complete
an informant version of the screening questionnaire.
Current informant ratings were obtained for 72 partici-
pants, and childhood ratings for 48 participants. The self-
rated screening data were used to allocate participants into
screen positive and negative groups for ADHD. Participants
screening positive for ADHD were invited to complete a re-
search diagnostic interview assessment. Participants who
failed to attend the diagnostic interview were offered up
to three further appointments. Following three missed
appointments, a final letter invited participants to contact
the research team to reschedule an appointment before the
assessment was recorded as “missing”.
Screening questionnaires
Participants completed DSM-IV 18-item self-report ADHD
screening questionnaires for both current and childhood
behaviour, using the 4-point (0, 1, 2, 3) rating scales from
Barkley [20]. A symptom is considered present if the indi-
vidual rates it as 2 (often) or 3 (very often). The Barkley
rating scales offer a total symptom count for the inatten-
tive domain and the hyperactive/impulsive domain (0–9
Huntley et al. BMC Psychiatry 2012, 12:223 Page 3 of 9
http://www.biomedcentral.com/1471-244X/12/223for each). We also asked participants to provide contact
details for an informant to provide similar ratings for both
current and childhood behaviour. Impairment questions
from the Barkley scales [20] were included that asked parti-
cipants to rate their level of impairment from ADHD
symptoms on a four-point scale for 10 domains of function
including: home life, work, social interactions, community
activities, education, relationships, money management,
driving, leisure activities and daily responsibilities. Partici-
pants also completed the Autism Quotient (AQ) [21]
which screens for autism spectrum disorder (ASD). Partici-
pants with above threshold AQ scores (>31) were invited
to complete an ADOS-G (Autism Diagnostic Observation
Schedule-Generic) [22]. The ADOS-G algorithm scores
participants as below threshold, autism spectrum or
autism. Further objective information was collected from
participants’ medical records, including details of current
substance use and co-morbid diagnoses made by other
mental health professionals. Previous convictions and pre-
vious suicide attempts were recorded as present or absent.
Diagnostic interview
Research diagnosis of ADHD was established using the
Diagnostic Interview for ADHD in Adults (DIVA 2.0;
www.divacenter.eu) [23]), conducted by trained research
assistants. All cases were reviewed by senior psychiatrists
from the Maudsley Adult ADHD clinic (PA and SM). The
interview systematically evaluates each of the DSM-IV
symptom items for both current and childhood symptoms,
and asks additional questions to establish impairment
from ADHD symptoms (impairment criteria), in two or
more settings (pervasiveness criteria) and the age of onset
of symptoms (age of onset criteria). Reliability between
interviewers over the first ten diagnostic interviews was
high (Table 2).
Diagnostic algorithm
The diagnostic algorithm for ADHD used the following
criteria: (i) 6 or more ADHD symptoms in either domain
from retrospective childhood rating scales; (ii) 4 or more
ADHD symptoms from either domain from current
ADHD symptom rating scales; (iii) Research diagnosis of
DSM-IV ADHD following application of diagnostic inter-
view for DSM-IV ADHD. This study was approved byTable 2 Inter-rater reliability for individual items on the







Reliability Overall 0.875 98% 95%
Child 0.900 95% 100%
Adult 0.850 100% 90%
Intra-class correlations (r) for total symptom scores and concordance rates (CR)
for diagnostic thresholds.the South London and Maudsley Research Ethics Com-
mittee and all participants gave informed consent before
taking part.
Results
Recruitment and screening stages are summarised in
Figure 1. All 226 patients completed T1 screening ques-
tionnaires of which 69% completed T2 ratings. Reasons
for missing T2 screeners included early self- or
disciplinary-discharge (n=23), refusal to take further part
in the study (n=15) and repeatedly missing T2 appoint-
ments (n=32).
Childhood ADHD screeners
Mean total childhood ADHD symptom scores were high-
est in the group treated for drug dependency (mean 29, SD
14) followed by the combined drug and alcohol group
(mean 24, SD 15) and the alcohol dependency group
(mean 17, SD 14). A one way ANOVA showed significant
effects of primary diagnosis (drug vs. alcohol vs. combined)
on childhood screener total score (p<0.001). Planned con-
trasts showed significantly higher ratings of ADHD symp-
toms for drug compared to alcohol participants (p<0.001),
but not between drug and combined drug and alcohol
groups (p=0.12).
T1 versus T2 ratings
These data are summarised in Table 3. Current ADHD
scores dropped significantly between T1 and T2 ratings
with a mean change of 8.6. We found that 52% of parti-
cipants with T1 and T2 data had a clinically meaningful
reduction of 8 or more points on the self-completed
ADHD rating scales, which is equivalent to a one-level
drop in the Clinical Global Impression Scale [24].
A 2x3 Mixed Model Factorial ANOVA on the time (T1
vs. T2) and primary diagnosis (drug vs. alcohol vs. com-
bined drug and alcohol) found a significant main effect
of time (p<0.001), indicating that self-rated ADHD symp-
tom scores are influenced by the detoxification treatment
process and/or withdrawal states following admission. A
significant effect of primary diagnosis was also found
(p<0.001) but no significant interaction between time
and primary diagnosis (p=0.34). Between subjects con-
trasts showed significant differences for ADHD ratings be-
tween the alcohol and combined drug & alcohol groups
(p<0.001), but not between drug and combined (p=0.28)
or alcohol and drug (p=0.11), indicating higher levels of
ADHD symptoms at T1 and T2 among those with drug
abuse compared to those with alcohol abuse alone.
Estimated prevalence of ADHD
There was an estimated prevalence rate for ADHD of
12.2% (Figure 2). Of these 73% met criteria for the com-





















































Figure 1 Flow of participants through screening stages.
Huntley et al. BMC Psychiatry 2012, 12:223 Page 4 of 9
http://www.biomedcentral.com/1471-244X/12/223and 9% for the inattentive subtype. The prevalence was
calculated using the proportion of participants completing
each step that did and did not fulfill ADHD screening and
assessment criteria. This in turn allowed us to calculate an
estimated prevalence rate of positive screens at each stage
which is not affected by attrition rates between screening
and assessment stages. To evaluate whether rates of
ADHD might differ in the groups that screened positive
for ADHD at T1 and T2, but did (or did not) attend for
diagnostic interviews; we compared the attendees to the
non-attendees. The participants who attended the diag-
nostic assessments showed no significant differences from
those that did not at T1. However they had significantly
higher score for inattentive (but not hyperactive-impul-
sive) symptoms at T2 (6.1 versus 4.3; p=0.025), suggesting
that the prevalence estimate based on available data might
be slightly inflated.
Broader definitions of ADHD
Broadening the diagnostic threshold, based on the DIVA
(diagnostic interview), only had a small impact on the
prevalence estimate. For example reducing the threshold
for diagnosing ADHD from ≥6 symptoms in childhoodTable 3 Mean (SD) ADHD screening scores for retrospective r
T2 in the total inpatient sample
Childhood T1 T2
Total score /54 21.09 23.03 14.65
(SD 15.0) (SD 12.5) (SD 12.1)
Inattentive symptoms /9 3.51 3.59 1.83
(SD 3.2) (SD 2.9) (SD 2.5)
Hyp/imp symptoms /9 3.29 3.46 2.30
(SD 3.0) (SD 2.6) (SD 2.6)
There is a significant reduction in ADHD symptoms following 1-week or more of tre
** Significant at p<0.001.to ≥4 only increased the overall prevalence estimate to
14.4%; and no additional cases were identified by de-
creasing the threshold for current symptoms to ≥4.Informant rating scales
64% of participants provided contact details for informants
of their current behaviour and 43% for childhood behav-
iour; and 50% of both sets of contacts returned screening
questionnaires. The correlations between self and inform-
ant reported symptoms are listed in Table 4. Informant rat-
ings of current ADHD symptoms correlated moderately
with self-reported symptoms and were similar to the
equivalent correlations in the control sample (r=0.47,
p<0.001). However, the participants with positive screens
for ADHD agreed far more strongly with their informants
than those who did not screen positive for ADHD (correla-
tions 0.62 to 0.66). Correlations between childhood self
and informant ratings were similar to those for current be-
haviour but were non-significant. Overall, participants and
informants were concordant for the 4+ screening criteria
in 64% of cases at T1, 50% of cases at T2; and 81% con-
cordance for the childhood 6+ criteria.atings from childhood and current symptoms at T1 and












Also positive at 
T1 (87.1%)
Negative at T1 
(12.9%) 
Also positive at 
T2 (60.0%)



















% POSITIVE AT 
EACH STAGE
COLUMN C.
% NEGATIVE AT 
EACH STAGE
Figure 2 Estimated prevalence of ADHD.
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As expected the SUD sample rated themselves as signifi-
cantly more impaired than controls (p<0.05). Among the
individuals with SUD there was a significant positive rela-
tionship between self-rated impairment and the severity of
ADHD symptoms in childhood and at both T1 and T2
(respectively: r=0.52, p<0.001; r=0.73, p<0.001; r=0.51,
p<0.001). Furthermore, greater impairment was signifi-
cantly negatively correlated with change scores between T1
and T2 (r=−0.23, p<0.01); indicating that participants with
greater impairment at T1 showed a smaller drop in ADHD
symptoms between T1 and T2. Lastly, within the SUD
population we compared the diagnosed ADHD cases to
the non ADHD cases. Those with ADHD had significantly
higher rates of self-reported impairments (see Figure 3)Table 4 Correlations between self and informant reports
Current behaviour informant report All participants n=72
Positive ADHD screen (childhood 6
Negative ADHD screeners n=56
Childhood behaviour informant report All participants n=47
Positive ADHD screeners (childhoo
Negative ADHD screeners n=27
** Significant at p<0.01 / *Significant at p<0.05.and were significantly more likely to have reported using
cocaine or amphetamines (Table 5), consumed more units
of alcohol per day and had more prior suicide attempts.
Also they had a trend for higher rates of depression, previ-
ous convictions and previous drug or alcohol dependency
treatment (Table 6).
Autism spectrum disorder
Only 4 participants out of 113 who completed the AQ
were above the threshold and of these only 1 met criteria
for possible ASD. Since the rates of ASD in this popula-
tion, based initially on self-report data, appear to be very
low, we did not pursue this line of investigation further.
Future studies should consider informant reports of aut-
istic behaviours at the screening stage, to exclude theSelf report
T1 T2
.372** .375*









































































Figure 3 Mean impairment scores at T1 (/3) (inpatient sample).
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self-report questionnaires.Discussion
Our main finding was that the estimated prevalence of un-
diagnosed ADHD within substance use disorder clinic
populations in South London is around 12%. This is of im-
portance as we also found evidence that those individuals
with both SUD and ADHD had significantly higher self-
rated impairments across several domains of daily life; and
higher rates of substance abuse and alcohol consumption,
suicide attempts and depression, recorded in their case
notes. Taken together these two findings highlight the nega-
tive impact of ADHD on the individual and the increased
burden they most likely place on services. When consider-
ing the generalisablity of these findings, a limitation of this
study is the focus on in-patient detoxification units in
London. Further work is therefore required to evaluate
rates and impact of ADHD among out-patient SUD popu-
lations and other national and international regions.Table 5 Drug use (past or current) in ADHD vs. non-ADHD gro
Heroin Amphetamine
ADHD (n=11) 45.5% 63.7%
Non-ADHD (n=182) 29.7% 6.6%
Likelihood Ratio 1.141 21.289
p value .285 <0.001**
** Significant at p<0.01.Impairments associated with comorbid ADHD and SUD
The finding of higher levels of impairment for ADHD
cases within the SUD sample appears to be robust since
we found indicators of impairment from both self-report
and more objective (case note) measures. Appropriate
assessment and management of ADHD in SUD patients
would therefore seem to be potentially important to im-
prove the general level of functional impairments and,
particularly, given our finding that ADHD is associated
with increased frequency of suicide attempts and depres-
sion. Whether treating ADHD in the context of SUD
improves depression has yet to be adequately studied;
yet we know that in people with ADHD symptoms such
as mood instability and low self-esteem respond well to
treatments for ADHD [25-28]. Another finding was that
the ADHD group had significantly higher use of stimu-
lants such as cocaine and amphetamine (although not
crack cocaine). One possible (but untested) explanation
for this, given that stimulants are routinely used to treat
ADHD in the general population, is that people with
ADHD are using stimulants as a form of self-treatment.ups





Table 6 Other indicators of impairment in ADHD vs. non-ADHD groups
Previous suicide attempts Comorbid depression diagnosis
ADHD (n=11) 54.5% 27.3%
Non-ADHD (n=183) 23.0% 35.0%
Likelihood Ratio 4.675 5.714
p value .029* .057
*Significant at p<0.05.
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with ADHD have a preference for drugs that are more
‘stimulating’, especially when injected or taken at high
dose. Further work is needed to address this issue.
Definition of ADHD and methodological issues
Our work attempted to address, as best we could, the in-
evitable methodological difficulties that might impact on
accurate estimation of prevalence rates for ADHD within
people with SUD. These include the potential for unreli-
able information from self-report questionnaires, difficul-
ties with retrospective recall of childhood symptoms and
the direct impact of drug and alcohol intoxication and
withdrawal states on ADHD-like symptoms. We therefore
attempted to measure ADHD symptoms before and after
detoxification, included independent informant ratings
whenever possible, compared these to population control
data, and completed research diagnostic interviews. One
additional confounder might arise if the study participants
considered a positive diagnosis of ADHD as a way to ob-
tain stimulant medication. However the study was not
linked directly to the treatment of ADHD and expecta-
tions for treatment with stimulants are currently low in
the UK, because in most cases ADHD in adults goes un-
recognised and untreated [3]. Based on the percentage of
patients who screened positive for ADHD in childhood
and adulthood and the proportion of those interviewed we
estimated an overall rate of ADHD of around 12% in our
sample, much higher than the equivalent estimated world-
wide prevalence of around 2.5% to 3.4% in non SUD
populations [2,4,29]. Using slightly broader criteria for
ADHD to reflect different approaches to the diagnosis of
adult ADHD being taken by different investigators and
clinicians, we found the estimated prevalence in our sam-
ple increased to a maximum of 15%. Overall, the esti-
mated prevalence of ADHD in our sample is far higher
than population rates, yet lower than those cited in some
previous studies of ADHD in SUD populations. There are
several potential reasons for these differences in the find-
ings from this and previous studies. One potential reason
was our stringent application of the DSM-IV criteria,
which might have led to an underestimate of the true rate
of ADHD in the SUD population for several reasons. First,
the inherent problem in collecting childhood data retro-
spectively might mean that some participants who metcurrent criteria for ADHD may have been unable to recall
sufficient examples of childhood symptoms. We recorded
‘unknown’ ratings in the diagnostic interview assessments
if participants could not provide sufficient information to
conclude that a symptom was present or absent and found
that on average 15% of childhood symptoms could not be
scored. Secondly, DSM-IV criteria only require that ‘some’
symptoms and impairments were present during early
childhood and do not specifically require ≥6 symptoms
from childhood so long at the symptom count criteria are
currently met as an adult. Nevertheless, we decided to take
the more stringent approach because of the lack of pro-
spective data from childhood and to guard against inclu-
sion of ADHD-like syndromes that might arise as a result
of chronic drug abuse in the absence of an underlying
ADHD diagnosis. Finally, we know that the current DSM-
IV criterion are not adjusted to take into account age-
related changes in the development of ADHD and there is
evidence that ≥ 4 symptoms in adults, rather than the
current ≥6 symptoms, is sufficient; indeed this change is
being considered for the fifth revision of the DSM that is
currently in preparation [3,30,31]. However, taking all
these alternative thresholds into account had only a minor
impact on our estimate of the prevalence of ADHD in the
SUD population.
The impact of drug detoxification on ADHD symptoms
We investigated the impact of drug intoxication and/or
the detoxification process by evaluating self-rated ADHD
symptom scores a few days after admission to the detoxifi-
cation unit and one week later, when they were detoxified
or stabilized on long term medication and no longer in a
withdrawal state. We found significant decreases in
ADHD symptoms of around 8-points (15% of the total
score), which is a clinically significant reduction in ADHD
symptoms and comparable to a one-level drop of the Clin-
ical Global Impression Scale [24]. In terms of our screen-
ing criteria this led to 40% of patients no longer meeting
screening criteria for ADHD at T2 compared to the T1.
Hence prior studies may have reported a higher preva-
lence than we found due to the confounding effect of drug
use and/or withdrawal symptoms. Other researchers have
noted mood disturbances during alcohol detoxification
[32] and it is therefore possible that ADHD-like symptoms
are also part of the withdrawal syndrome. Despite this, we
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remained clinically significant following completion of the
detoxification process. One implication is that although
the withdrawal process may impact on the level of ADHD
symptoms (and this should be taken into account when
evaluating ADHD in SUD patients) there still remain a
significant number of individuals with clinically significant
symptoms of ADHD – and these require treatment.
Clinical implications
Our findings suggest that clinical evaluations for ADHD
are probably best completed once detoxification or
stabilization for drug or alcohol dependency has been com-
pleted. However this suggestion may be difficult to imple-
ment in community patients. Furthermore, once diagnosis
of ADHD has been established it will be important to offer
treatment. Use of some pharmacological treatments (such
as use of stimulants) is complex, however, in those with a
current SUD. Nevertheless therapeutic nihilism is not an
option as treatment of underlying ADHD may be import-
ant to the success of drug treatment programs for some
individuals. It might be advisable to use the more stringent
screening criteria of 6+ symptoms in either domain to
identify those that need full clinical evaluation for ADHD,
or to recognise the need for detailed ADHD assessment in
a higher proportion of cases. Moreover it may be more ap-
propriate to use non stimulant medications such as ato-
moxetine, as a first line treatment. Further work is
required to address this issue, and the potential for using
CBT based therapies for ADHD in this complex popula-
tion. Obtaining informant data on ADHD symptoms for
childhood and for current symptoms proved difficult in
this population. The reasons for this were not investigated
here, but likely reflect the often poor relationships that
many SUD patients have with their family and friends.
Therefore in clinical practice it will also often be the case
that the diagnostic assessment of ADHD will depend on
self-report alone. We were able to investigate the validity
of these self-reported data by comparison of self-report
with informant reported data in a subset of our sample and
a comparison control sample. These showed moderate cor-
relations between raters which were similar to that seen in
non-SUD control populations. For the most impaired sub-
group however, who were screening positive for ADHD
based on their self-report, there was a far higher correl-
ation with informant report for current ADHD ratings of
around 0.62–0.65. We therefore suggest that while discrep-
ancies between raters exist for ADHD rating scales, this
does not appear to be different for SUD compared to con-
trol populations. Furthermore ratings showed moderately
high levels of agreement for the group of patients with
ADHD. Previous research has shown that in general people
with ADHD tend to rate their symptoms lower than infor-
mants [20] perhaps reflecting difficulties in self-evaluationof ADHD symptoms. Our research does not support this
finding within the SUD population investigated here.
When we completed diagnostic interviews with 26 people
that screened positive for ADHD on the basis of their self-
rated symptoms we found that only 61% met full criteria
for ADHD. The clinical implication of this finding is that
the diagnosis of ADHD in patients with SUD should not
depend solely on rating scale data, but rather on the
basis of more objective examples of symptoms charac-
teristic of ADHD, as applied here using the DIVA inter-
view. Rating scales are a valuable tool for screening for
ADHD but should not be used as a replacement for a
full diagnostic assessment by clinical interview. Further-
more, while informant reports are helpful in supporting
the diagnosis, the moderately high correlations with
self-report suggest that in most cases self-report alone
should be sufficient. For in-patient SUD units it should
also be feasible to observe patients for level of restless-
ness, problems with self-organisation, inattentiveness,
impulsive responses and poor emotional regulation, that
are characteristic of ADHD in adults.
Conclusions
This study applied stringent ADHD diagnostic criteria,
necessary to avoid mistaking withdrawal states and other
mental health problems for ADHD. This resulted in
identification of a relatively small ADHD group com-
pared to other studies relying only on self-report screen-
ing questionnaires. Despite this, our findings confirm
high rates of ADHD within SUD populations that are
approximately 5-fold higher than general population
rates. Furthermore SUD patients with high levels of
ADHD were functionally more impaired (including
higher rates of suicide attempts). This study highlights
the importance of identifying the sub-group of people
with both SUD and ADHD. Further studies are required
to evaluate the effectiveness of targeted treatments for
ADHD within SUD patient populations.
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